Feasibility Study of Geko vs. IPCs in Trauma (GIFT Pilot)
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Feasibility Study of a Randomized Controlled Trial of a Novel Device vs. Intermittent Pneumatic Compression for Prevention of Venous Thromboembolism in Trauma Patients|
- Feasibility of completing a larger, phase III trial with DVT incidence as primary outcome [ Time Frame: earliest of when 40th subject is enrolled or 18 months from study start ]
This endpoint will be considered to have been met if, after enrollment of 40 subjects, both of the following conditions are met:
i. the time from enrollment of the first subject to enrollment of the 40th subject is less than 18 months; AND ii. all secondary outcomes are evaluable for at least 80% of subjects.
- Compliance [ Time Frame: Twice daily (excluding weekends and holidays), until subject exits study ]
Study personnel will assess compliance. For subjects randomized to gekoTM, the subject will be considered compliant for the visit if:
i) one gekoTM device is attached to each leg; AND ii) a muscle contraction caused by each device can be visualized with the subject's leg at rest;
For subjects randomized to IPCs, the subject will be considered compliant for the visit if:
i) one calf sleeve is affixed to each leg; AND ii) both sleeves are visibly inflating and deflating.
A compliance statistic will be computed for each subject by dividing the number of compliant observations by the total number of observations. A mean value will be determined for each study arm. The means will be compared using a two-tailed Student's t-test with alpha = 0.05. The proportion of subjects with a compliance statistic of at least 80% will be calculated. The proportion of subjects with at least 80% compliance will be compared between study treatment arms using Fisher's exact test.
- Development of venous thromboembolism [ Time Frame: At time subject exits from study (day 10 or earlier) ]
Development of VTE defined either by 1) a positive screening duplex ultrasound of the deep veins of the legs, or 2) an objectively verified clinical diagnosis of DVT and/or PE, established by patient's treating physician.
The proportion of patients in each arm who develop VTE during the study will be calculated. The sample is projected to be too low to enable any further statistical comparison of efficacy in prevention of VTE.
- Tolerability [ Time Frame: At time subject exits from study (day 10 or earlier) ]
The tolerability questionnaire will be administered by the research coordinator on the day of study exit.
The proportion of subjects selecting each of the possible answers for each of the questions on the tolerability questionnaire will be computed for each study arm. Further statistical comparison between the groups will not be undertaken for the tolerability questionnaire, but the data will be used for hypothesis-generation regarding specific causes of increased or decreased tolerability between the devices.
- Venous and arterial physiological flow [ Time Frame: At time subject exits from study (day 10 or earlier) ]
Mean values and standard error for each study arm will be computed for the volume flow and peak velocity in the superficial femoral vein and femoral artery using pulsed Doppler by duplex ultrasound.
The values will be compared using a two-tailed Student's t-test (alpha = 0.05).
|Study Start Date:||July 2013|
|Study Completion Date:||August 2014|
|Primary Completion Date:||August 2014 (Final data collection date for primary outcome measure)|
For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
Other Name: neuromuscular stimulation device
Active Comparator: IPCs
The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
devices that pneumatically compress the leg, resulting in increased venous blood flow.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01835990
|Hamilton General Hospital|
|Hamilton, Ontario, Canada, L8L 2X2|
|Principal Investigator:||Vinai C Bhagirath, MD FRCP(C)||McMaster University|